Hypermarcas (OTCMKTS:HYPMY) Sees Significant Decrease in Short Interest

Hypermarcas (OTCMKTS:HYPMY) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totaling 1,675 shares, a decline of 60.7% from the September 30th total of 4,266 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 1,020,623 shares, the days-to-cover ratio is presently 0.0 days.

Hypermarcas Stock Performance

Hypermarcas stock opened at $3.99 on Friday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.86 and a quick ratio of 1.26. Hypermarcas has a 12 month low of $3.39 and a 12 month high of $5.77. The company has a fifty day moving average price of $4.66 and a two-hundred day moving average price of $4.43. The company has a market cap of $2.81 billion, a PE ratio of 7.98 and a beta of 0.65.

Hypermarcas (OTCMKTS:HYPMY) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. Research analysts expect that Hypermarcas will post 0.51 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group upgraded shares of Hypermarcas to a “strong-buy” rating in a report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy”.

Hypermarcas Company Profile

Hypermarcas SA was a Brazilian consumer-health and pharmaceutical company that later changed its corporate name to Hypera SA The company was established as a diversified consumer-products business and, over time, shifted its focus toward pharmaceuticals and healthcare products.

Hypera develops, manufactures and markets prescription medicines, generic and branded-generic drugs, over-the-counter products, vitamins and nutritional supplements. Its portfolio has included well-known Brazilian consumer-health brands such as Neosaldina, Doril, Engov, Benegrip and Addera D3, serving categories including pain relief, cold and flu treatment, digestive health and vitamins.

The company’s principal market is Brazil, where its products are distributed through pharmacies, retailers and other healthcare channels.